Skip to main content
. 2020 Oct 27;22:113. doi: 10.1186/s13058-020-01351-1

Table 1.

Demographic and clinical characteristics of cohorts 1 and 2

Subtype Cohort 1 Cohort 2
HC (%) Luminal (%) TN (%) HER2-enriched (%) Luminal (%) TN (%) HER2-enriched (%)
Total 98 138 143 127 10 10 10
Age
 Mean 44.99 61.3 57.3 59.6 66 64.1 62.1
 < 40 33 (33.6) 5 (3.6) 17 (11.9) 6 (4.7) 1 (10) 0 0
 40–49 26 (26.5) 18 (13.0) 24 (16.8) 25 (19.6) 0 1 (10) 2 (20)
 50–59 24 (24.5) 43 (31.2) 37 (25.9) 34 (26.8) 3 (30) 2 (20) 3 (30)
 60–69 14 (14.3) 37 (26.8) 31 (21.7) 31 (24.4) 1 (10) 3 (30) 3 (30)
 > 70 1 (1.0) 35 (25.3) 34 (23.7) 31(24.4) 5 (50) 4 (40) 2 (20)
Histological grade
 1 34 (24.6) 0 0 0 0 0
 2 62 (44.9) 52 (36.4) 34 (26.8) 0 0 0
 3 42 (30.4) 91 (63.6) 93 (73.2) 10 (100) 10 (100) 10 (100)
Tumor size
 < 2 cm 58 (42.0) 68 (47.6) 43 (33.8) 2 (20) 2 (20) 1 (10)
 2.0–5.0 cm 57 (41.3) 72 (50.3) 65 (51.2) 5 (50) 8 (80) 8 (80)
 > 5 cm 23 (16.7) 3 (2.1) 18 (14.2) 3 (30) 0 1 (10)
 Not available 0 0 1 (0.8) 0 0 0
PR status
 Positive 138 (100) 0 (0) 0 (0) 8 (80) 0 (0) 12 (9.4)
 Negative 0 (0) 143 (100) 127 (100) 2 (20) 10 (100) 115 (90.6)
HER2 IHC
 Positive 119 (86.2) 0 (0) 12 (9.4) 0 (0) 0 (0) 10 (100)
 Negative 19 (13.8) 143 (100) 115 (90.6) 10 (100) 10 (100) 0 (0)